Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prepubertal children with GHD (either isolated or as part of a multiple pituitary hormone deficiency) in Tanner stage 1 (Tanner 1982) aged:~  * Boys: 3-12 years, inclusive~ * Girls: 3-11 years, inclusive~* Impaired height (HT) defined as at least 2.0 standard deviations (SD) below the mean height for chronological age and sex (HT SDS ≤ -2.0) according to the 2000 CDC Growth Charts for the United States Methods and Development, available at http://www.cdc.gov/growthcharts/~* Diagnosis of GHD confirmed by 2 different GH stimulation tests, defined as a peak GH level of ≤10 ng/mL, determined with a validated assay~* Bone age (BA) at least 6 months less than chronological age~* Baseline IGF-1 level of at least 1 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS ≤-1)~* Written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is able to read, understand, and sign)~Exclusion Criteria:~* Children with a body weight below 12 kg~* Prior exposure to recombinant hGH or IGF-1 therapy~* Children with past or present intracranial tumor growth as confirmed by a sellar MRI scan (with contrast) at Screening (MRI results from up to 6 months prior to Screening may be accepted)~* Children with psychosocial dwarfism~* Children with idiopathic short stature~* History or presence of malignant disease; any evidence of present tumor growth~* Closed epiphyses~* Major medical conditions and/or presence of contraindication to hGH treatment~* Participation in any other trial of an investigational agent within 3 months prior to Screening

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- TransCon hGH (Type: EXPERIMENTAL): Once weekly subcutaneous injection of TransCon hGH
- human growth hormone (Genotropin) (Type: ACTIVE_COMPARATOR): Once daily subcutaneous injection of Genotropin

Based on this trial design, predict the completion outcome and termination type (if applicable).